The Team
For more than three decades, we have been leading advancements in gene therapy, focusing on improving mRNA stability. Our contributions are crucial in addressing cancer and genetic diseases, and have achieved commercial success worldwide, benefiting major companies like BioNTech, Sanofi, and Genentech.
mRNA Modification for Increased Protein Synthesis
EP2502938A1
2011
Efficient mRNA Delivery System
WO2012149280A1
2012
mRNA-Based Cancer Vaccine Platform
US20130115294A1
2013
Enhanced mRNA Stability Method
(applied in multiple clinical trials)
US20100233757
2010
mRNA Cap Analog Technology
(utilized in advanced genetic vaccine development)
US20110092574
2010
Previous commercializations
BioNTech
ExploRNA
![Adam Mamot - phD at Max Planck Institute of Biochemistry]( "Adam Mamot - coauthor of dual tag rna labeling method")
>80 publications
>1500 citiations
28 H-Index
Ph.D. at Max Planck Institute of Biochemistry
Adam Mamot
Assistant professor at University of Warsaw
Joanna Kowalska
>140 publications
>2550 citiations
34 H-Index
Professor at University of Warsaw
Jacek Jemielity
![Joanna Kowalska - assistant professor at University of Warsaw, CSO of Explorna Therapeutics, author of many rna modification inventions.]( "Joanna Kowalska - coauthor of dual tag rna labeling method")
![Jacek Jemielity - Professor at University of Warsaw, President and CEO of Explorna Therapeutics, author of numerous RNA modification inventions, and coauthor of the Dual Tag RNA Labeling Method.]( "Jacek Jemielity - Coauthor of Dual Tag RNA Labeling Method")
![Photo of the Jemielity Group, also known as the ChemBioBioChem research team. This dedicated group focuses on the chemical synthesis, properties, and applications of modified nucleotides and nucleic acids. They advance chemical synthesis methods for nucleotide analogs, design new modified nucleotides for molecular biology tools, and integrate nucleotides with labels, tags, and innovative materials. A key interest area includes the development of eukaryotic mRNA modifications, such as cap analogs, with potential medical applications. The team is part of the Laboratory of Chemical Biology and Chemical Biophysics, within the New Technologies Center and the Department of Biophysics at the University of Warsaw.]( "Jemielity Group - ChemBioBioChem Research Team")
